(Q38522309)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

review article

1 reference

title

Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Guangbiao Zhou

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

J-Q Mi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

S-J Chen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

X-J Yan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Z Chen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

English

0 references

publication date

9 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json

Journal of Internal Medicine

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

278

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

627-642

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json

Acute Promyelocytc Leukemia

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Acute promyelocytic leukemia: from highly fatal to highly curable

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

TBLR1 fuses to retinoid acid receptor α in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

OBFC2A/RARA: a novel fusion gene in variant acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

GTF2I-RARA is a novel fusion transcript in a t(7;17) variant of acute promyelocytic leukaemia with clinical resistance to retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Retinoic acid and arsenic for treating acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Role of the histone deacetylase complex in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Genome-wide functions of PML-RARα in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Acute promyelocytic leukaemia: novel insights into the mechanisms of cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

PML targeting eradicates quiescent leukaemia-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Impairment of p53 acetylation, stability and function by an oncogenic transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

PML-RAR{alpha} and Dnmt3a1 cooperate in vivo to promote acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Retinoic acid in the treatment of acute promyelocytic leukemia: inefficacy of the 13-cis isomer and induction of complete remission by the all-trans isomer complicated by thromboembolic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Retinoic acid resistance in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

RIG-I plays a critical role in negatively regulating granulocytic proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

RA-inducible gene-I induction augments STAT1 activation to inhibit leukemia cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

RIG-I modulates Src-mediated AKT activation to restrain leukemic stemness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

How acute promyelocytic leukaemia revived arsenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Rapid reduction in breast cancer mortality with inorganic arsenic in drinking water

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Arkadia, a novel SUMO-targeted ubiquitin ligase involved in PML degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12376

21 January 2018

Identifiers

DOI

10.1111/JOIM.12376

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26058416%20AND%20SRC:MED&resulttype=core&format=json